Skip to main navigation
Compass Therapeutics
  • Home
  • About
  • Platform
  • Pipeline
  • Join Us
  • Investors
  • Contact

News Releases

Investor Menu
  • Home
  • News & Events
    • News Releases
    • Events
    • Presentations
    • In the News
  • Stock Information
    • Stock Quote & Chart
    • Historic Price Lookup
    • Investment Calculator
    • Analyst Coverage
  • Corporate Governance
    • Documents & Charters
    • Leadership Team
    • Board of Directors
    • Committee Composition
  • Financial & FIlings
    • SEC Filings
    • Annual Meeting
    • Annual Reports
    • Quarterly Results
May 09, 2022
Compass Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress
Additional Formats
PDF Version
May 05, 2022
Compass Therapeutics to Present at the Bank of America Securities 2022 Healthcare Conference on Thursday, May 12, 2022 at 11:20 a.m. PT
Additional Formats
PDF Version
May 04, 2022
Compass Therapeutics Reports Positive Interim Phase 2 Data of CTX-009 in Combination with Paclitaxel in Biliary Tract Cancers
Additional Formats
PDF Version
May 03, 2022
Compass Therapeutics to Host Conference Call Highlighting Clinical Data from CTX-009
Additional Formats
PDF Version
Apr 26, 2022
Compass Therapeutics Announces Appointment of Two New Directors to its Board
Additional Formats
PDF Version
Apr 08, 2022
Compass Therapeutics Presents Data on CTX-8371, a Bispecific Antibody Targeting PD-1 and PD-L1, at the 2022 AACR Annual Meeting
Additional Formats
PDF Version
Mar 30, 2022
Compass Therapeutics Announces Presentation on CTX-8371, A Bispecific Antibody Targeting PD-1 and PD-L1, at the 2022 AACR Annual Meeting in New Orleans
Additional Formats
PDF Version
Mar 21, 2022
Compass Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
Additional Formats
PDF Version
Jan 20, 2022
Compass Therapeutics Announces US FDA Clearance of Investigational New Drug Application for a Phase 2 Study of CTX-009, a Bispecific Antibody That Simultaneously Targets Delta-like Ligand 4 (DLL4) and Vascular Endothelial Growth Factor A (VEGF-A)
Additional Formats
PDF Version
Jan 07, 2022
Compass Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
Additional Formats
PDF Version

IR Contact

ir@compasstherapeutics.com

Media Contacts

media@compasstherapeutics.com

Email Alerts

  • © 2022 Compass Therapeutics, Inc.
  • Terms & Conditions
  • Privacy Policy
  • Home
  • About
  • Platform
  • Pipeline
  • Join Us
  • Investors
  • Contact